Senolytic peptide

FOXO4-DRI

An experimental senolytic that clears worn-out 'zombie' cells.

Early / anecdotal

Overview

FOXO4-DRI is an experimental senolytic peptide - a compound designed to selectively clear senescent cells, sometimes called 'zombie cells.' Senescent cells are cells that have stopped dividing but have not died; they accumulate with age and secrete inflammatory signals that can degrade surrounding tissue. FOXO4-DRI works by disrupting the interaction between two proteins, FOXO4 and p53, that senescent cells rely on to stay alive. Breaking that interaction triggers the senescent cell's own death (apoptosis) while sparing normal healthy cells. Its sole goal in the current data is longevity - specifically the cellular aging and healthspan angle. The evidence is classified as anecdotal, meaning it is based primarily on animal studies; human trial data is not yet available. This is among the more experimental compounds in the PepDepo catalog. Administration is by subcutaneous injection. Dosing, timing, and cycle length are all set per protocol at consult. Cycles are described as pulsed and infrequent - not continuous daily use. There are no stacking partners or avoidance conflicts listed. There is one important contraindication: FOXO4-DRI is excluded for anyone with a history of cancer, because its mechanism of inducing cell death requires careful clinical evaluation in that context. Given the highly experimental status and the cancer-history exclusion, a thorough consult is essential. Exact dosing is set with a licensed provider in the PepDepo network at your consult.

At a glance

Route

SC injection

Dose

Per protocol

Frequency

Short pulsed courses

Timing

Per protocol

Cycle

Pulsed, infrequent

Safety

Highly experimental; animal data only.

Regulatory: Experimental.

Not appropriate if: cancer-history.

Questions

What is a senescent cell and why does clearing them matter?⌄

Senescent cells are cells that have stopped dividing but have not died. They accumulate with age and release inflammatory signals that can damage nearby tissue. Clearing them is a longevity strategy aimed at reducing that chronic inflammatory load.

How does FOXO4-DRI clear senescent cells?⌄

It disrupts the interaction between FOXO4 and p53 - two proteins that senescent cells rely on to survive. When that interaction is blocked, senescent cells undergo apoptosis (programmed death) while normal cells are spared.

How is it taken?⌄

FOXO4-DRI is given by subcutaneous injection. Cycles are pulsed and infrequent rather than daily. Exact dose, frequency, and cycle length are all set at consult.

Who should NOT use FOXO4-DRI?⌄

Anyone with a history of cancer is excluded. Because the mechanism involves inducing cell death, clinical review in that context is required and the compound is currently contraindicated.

How strong is the current evidence?⌄

The evidence is classified as anecdotal, based primarily on animal data. There are no large human clinical trials completed at this time. This is one of the more experimental compounds in the catalog.

Is this safe for general use?⌄

It is highly experimental. The animal data is promising but human safety data is limited. All use is under clinician supervision, with a thorough consult required before starting.

What goals does FOXO4-DRI address?⌄

Its single listed goal is longevity - specifically supporting cellular aging and healthspan by removing senescent cells.

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.